- Home
- CVAC vs GSBD Comparison
CVAC vs GSBD Comparison
Compare CVAC & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- GSBD
- Stock Information
- Founded
- CVAC 2000
- GSBD 2012
- Country
- CVAC Germany
- GSBD United States
- Employees
- CVAC N/A
- GSBD N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- GSBD Finance: Consumer Services
- Sector
- CVAC Health Care
- GSBD Finance
- Exchange
- CVAC Nasdaq
- GSBD Nasdaq
- Market Cap
- CVAC 1.2B
- GSBD 1.4B
- IPO Year
- CVAC 2020
- GSBD N/A
- Fundamental
- Price
- CVAC $5.48
- GSBD $11.25
- Analyst Decision
- CVAC Hold
- GSBD Sell
- Analyst Count
- CVAC 3
- GSBD 2
- Target Price
- CVAC $6.83
- GSBD $12.00
- AVG Volume (30 Days)
- CVAC 789.9K
- GSBD 658.1K
- Earning Date
- CVAC 08-18-2025
- GSBD 08-07-2025
- Dividend Yield
- CVAC N/A
- GSBD 11.39%
- EPS Growth
- CVAC N/A
- GSBD 52.30
- EPS
- CVAC 0.87
- GSBD 1.24
- Revenue
- CVAC $566,039,775.00
- GSBD $402,124,000.00
- Revenue This Year
- CVAC N/A
- GSBD N/A
- Revenue Next Year
- CVAC $24.04
- GSBD N/A
- P/E Ratio
- CVAC $6.35
- GSBD $9.05
- Revenue Growth
- CVAC 787.60
- GSBD N/A
- 52 Week Low
- CVAC $2.37
- GSBD $9.51
- 52 Week High
- CVAC $5.72
- GSBD $14.54
- Technical
- Relative Strength Index (RSI)
- CVAC 60.60
- GSBD 44.29
- Support Level
- CVAC $5.41
- GSBD $10.97
- Resistance Level
- CVAC $5.54
- GSBD $11.62
- Average True Range (ATR)
- CVAC 0.05
- GSBD 0.24
- MACD
- CVAC -0.01
- GSBD -0.01
- Stochastic Oscillator
- CVAC 73.68
- GSBD 29.13
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About GSBD Goldman Sachs BDC Inc.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company's origination strategy focuses on leading the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.